Tyra Biosciences, Inc. has announced the commencement of dosing for the first patient in its Phase 2 SURF302 clinical trial, evaluating the efficacy and safety of TYRA-300 in patients with low-grade, intermediate risk non-muscle invasive bladder cancer (IR NMIBC). TYRA-300 is currently the only orally administered investigational agent in clinical development for this condition. The trial aims to enroll up to 90 participants across multiple sites in the United States. Participants will receive either 50 mg or 60 mg of TYRA-300 once daily. The study's primary endpoint is the complete response rate at three months, with initial data expected in the first half of 2026. Secondary endpoints include recurrence metrics and safety evaluations. Results from the trial have not yet been presented.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。